Pharmacologic Approaches to Diabetes Management: Glucagon-Like Peptide-1 Based Therapies
While glucose control is paramount for patients with diabetes, the American Diabetes Association (ADA) Standards of Care 2023 Diabetes guidelines also emphasize the importance of managing comorbidities that can complicate diabetes management. Subsequently, the guidelines highlight the benefits of glucagon-like peptide 1-based therapies. This course will review glucagon-like peptide-1-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs. Dosing regimens, side effects, and monitoring parameters will be discussed. The role of GLP-1-based therapies within therapeutic regimens for patients with Type 2 diabetes will be discussed in the context of the updated Standards of Care in Diabetes 2023 guidelines.
Compare and contrast available glucagon-like peptide-1-based medications
Identify side effects and contraindications of glucagon-like peptide-1-based medications
Identify when to utilize glucagon-like peptide-1-based medications within a therapeutic regimen for patients with Type 2 diabetes
Recall patient counseling points related to the use of glucagon-like peptide-1-based medications
II. Guidelines for Managing Diabetes and Comorbidities
1. Exenatide (Byetta, Bydureon, Bydureon BCise)
2. Liraglutide (Victoza)
3. Insulin Degludec/Liraglutide (Xultophy 100/3.6)
4. Dulaglutide (Trulicity)
5. Lixisenatide (Adylxin)
6. Insulin Glargine/Lixisenatide (Soliqua 100/33)
7. Semaglutide (Ozempic)
8. Semaglutide (Rybelsus)
9. Side Effects and Monitoring
III. GIP/GLP-1 RAs
3. Side Effects
4. Contraindications and Warnings
IV. Choice of Glucose-Lowering Therapy
1. Type 2 Diabetes Mellitus
2. Cardiovascular and Renal Protection
3. Short-Acting vs. Long-Acting Agents
4. Glycemic Control
5. Weight Loss
6. Combination Therapy
7. Renal and Hepatic Disease
V. Patient Counseling Points
1. Use and Administration
2. Injection Technique
- Read the course objectives and faculty planner disclosure
- Read the course material
- Complete the post-test with a minimum score of 70% and complete the course evaluation form.
- Results are automatically submitted to CPE Monitor
Faculty Planner Disclosure
The following individuals were involved in the development of this activity: Liz Fredrickson, PharmD, BCPS and Pamela Sardo, PharmD, BS. Pamela Sardo, Pharm.D., B.S., was an employee of Rhythm Pharmaceuticals until March 2022 and has no conflicts of interest or relationships regarding the subject matter discussed. There are no financial relationships relevant to this activity to report or disclose by any of the individuals involved in the development of this activity.
Unlabeled Use Disclosures
The information provided in this course is general in nature and it is solely designed to provide participants with continuing education credit(s). This course and materials are not meant to substitute for the independent, professional judgment of any participant regarding that participant’s professional practice, including but not limited to patient assessment, diagnosis, treatment and/or health management. Medical and pharmacy practices, rules, and laws vary from state to state, and this course does not cover the laws of each state; therefore, participants must consult the laws of their state as they relate to their professional practice. Healthcare professionals, including pharmacists and pharmacy technicians, must consult with their employer, healthcare facility, hospital, or other organization, for guidelines, protocols, and procedures they are to follow. The information provided in this course does not replace those guidelines, protocols, and procedures but is for academic purposes only, and this course’s limited purpose is for the completion of continuing education credits. Participants are advised and acknowledge that information related to medications, their administration, dosing, contraindications, adverse reactions, interactions, warnings, precautions, or accepted uses are constantly changing, and any person taking this course understands that such person must make an independent review of medication information prior to any patient assessment, diagnosis, treatment and/or health management. Any discussion of off-label use of any medication, device, or procedure is informational only and such uses are not endorsed hereby. Nothing contained in this course represents the opinions, views, judgments, or conclusions of RxCe.com LLC. RxCe.com LLC is not liable or responsible to any person for any inaccuracy, error, or omission with respect to this course, or course material.
Computer Hardware/Software Requirements
Please ensure the device you plan to use meets these requirements and specifications:
- Operating System: Windows 7,8,10, or 11 /Mac OS X 10.9 or later/iOS/Android
- Supported Browsers: Microsoft Edge, Firefox, Google Chrome, Safari, Opera
- A connection to the internet
- For Live Webinars or Conferences: GoToWebinar application for iOS, Android, Mac, or PC. You cannot 'call into' a live conference.
- Target Audience: Pharmacy Tech
- Contact Hours: 1.0
- Activity Release Date: 6/24/2023
- Activity Expiration Date: 6/24/2026
- Activity Type: Knowledge
- UAN: 0669-0000-23-099-H01-T
- Topic: Disease State Management/Drug Therapy
- CeBroker Number: 20-944635
Preview the Materials:
RxCe.com, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
RxCe.com, LLC, offers pharmacy technician continuing education courses for PTCB recertification. Pharmacy technician courses are indicated both in the Target Audience description and the ACPE UAN which will end with a "T".